Nikolakopoulou Aggeliki, Peppa Vasiliki, Alexiou Antigoni, Pissakas George, Terzoudi Georgia, Karaiskos Pantelis
Laboratory of Health Physics, Radiobiology & Cytogenetics, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Centre for Scientific Research ''Demokritos'', 15310 Athens, Greece.
Medical Physics Laboratory, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Cancers (Basel). 2021 Dec 29;14(1):146. doi: 10.3390/cancers14010146.
While rapid technological advances in radiotherapy techniques have led to a more precise delivery of radiation dose and to a decreased risk of side effects, there is still a need to evaluate the efficacy of the new techniques estimating the biological dose and to investigate the radiobiological impact of the protracted radiotherapy treatment duration. The aim of this study is to compare, at a cytogenetic level, advanced radiotherapy techniques VMAT and IMRT with the conventional 3D-CRT, using biological dosimetry. A dicentric biodosimetry assay based on the frequency of dicentrics chromosomes scored in peripheral blood lymphocytes from prostate cancer patients and PC3 human prostate cancer cell line was used. For each patient blood sample and each subpopulation of the cultured cell line, three different irradiations were performed using the 3D-CRT, IMRT, and VMAT technique. The absorbed dose was estimated with the biodosimetry method based on the induced dicentric chromosomes. The results showed a statistically significant underestimation of the biological absorbed dose of ~6% for the IMRT and VMAT compared to 3D-CRT irradiations for peripheral blood lymphocytes, whereas IMRT and VMAT results were comparable without a statistically significant difference, although slightly lower values were observed for VMAT compared to IMRT irradiation. Similar results were obtained using the PC3 cell line. The observed biological dose underestimation could be associated with the relative decreased dose rate and increase irradiation time met in modulated techniques compared to the conventional 3D-CRT irradiations.
虽然放射治疗技术的快速技术进步已使辐射剂量的传递更加精确,且副作用风险降低,但仍有必要评估估算生物剂量的新技术的疗效,并研究延长放疗疗程的放射生物学影响。本研究的目的是在细胞遗传学水平上,使用生物剂量测定法,将先进的放疗技术容积调强弧形放疗(VMAT)和调强适形放疗(IMRT)与传统的三维适形放疗(3D-CRT)进行比较。采用基于前列腺癌患者外周血淋巴细胞和PC3人前列腺癌细胞系中双着丝粒染色体频率评分的双着丝粒生物剂量测定法。对于每个患者的血样和培养细胞系的每个亚群,使用3D-CRT、IMRT和VMAT技术进行三种不同的照射。基于诱导的双着丝粒染色体,用生物剂量测定法估算吸收剂量。结果显示,与外周血淋巴细胞的3D-CRT照射相比,IMRT和VMAT的生物吸收剂量在统计学上显著低估了约6%,而IMRT和VMAT的结果具有可比性,无统计学显著差异,尽管与IMRT照射相比,VMAT的值略低。使用PC3细胞系也获得了类似的结果。观察到的生物剂量低估可能与调强技术中与传统3D-CRT照射相比相对降低的剂量率和延长的照射时间有关。